Novartis' CDK4/6 inhibitor Kisqali has claimed a broad FDA approval in early breast cancer that could give it an edge over class rival Verzenio from Eli Lilly. The US regulator has cleared Kisqali ...

NICE has backed NHS use of Novartis’ CDK4/6 inhibitor Kisqali alongside fulvestrant for breast cancer patients in England and Wales, three months after rejecting it on cost grounds, via the ...

The FDA recently expanded the approval of the breast cancer drug Kisqali to treat patients with earlier stages of the disease. Thousands of women diagnosed with early-stage breast cancer will have ...

“If approved, Kisqali could provide an effective and tolerable adjuvant treatment option to mitigate the risk of recurrence in a broader patient population, particularly for patients who ...

Novartis announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting marketing authorization ...

EMA's CHMP issued a positive opinion for Novartis' Kisqali for high-risk early breast cancer. Kisqali showed a 25.1% reduced risk of cancer recurrence in Phase 3 NATALEE trial. The CHMP ...

Novartis said the European Medicines Agency has recommended its Kisqali cancer drug for market authorization. The drugmaker said Friday that the EMA's Committee for Medicinal Products for Human ...

Hexagonal close packing is one of two crystal structures that derive from stacking close-packed-planes of hard sphere atoms. In the HCP structure only two stacking ...

Q3 2024 Earnings Call Transcript October 29, 2024 Novartis AG beats earnings expectations. Reported EPS is $2.06, expectations were $1.96. Operator: Good morning and good afternoon, and welcome to the ...

Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (EMA) recommended granting approval to the breast cancer drug Kisqali ...